Loading...
XNASCTMX
Market cap88mUSD
Dec 26, Last price  
1.13USD
1D
5.61%
1Q
-5.83%
Jan 2017
-89.72%
IPO
-90.89%
Name

CytomX Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:CTMX chart
P/E
—
P/S
0.87
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
12.12%
Rev. gr., 5y
11.21%
Revenues
101m
+90.38%
888,0005,077,0007,712,00015,043,00071,623,00059,502,00057,489,000100,362,00069,573,00053,163,000101,214,000
Net income
-569k
L-99.42%
-15,143,000-30,310,000-35,374,000-58,900,000-43,099,000-84,604,000-102,238,000-32,885,000-80,648,000-97,299,000-569,000
CFO
-56m
L-49.42%
-8,008,00031,802,000-27,415,000-2,032,000170,373,000-75,521,000-140,480,0005,259,000-119,031,000-110,788,000-56,035,000
Earnings
Mar 10, 2025

Profile

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
URL
https://cytomx.com/
IPO date
Oct 08, 2015
Employees
116
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
101,214
90.38%
53,163
-23.59%
69,573
-30.68%
Cost of revenue
107,698
160,354
159,193
Unusual Expense (Income)
NOPBT
(6,484)
(107,191)
(89,620)
NOPBT Margin
Operating Taxes
3,892
(2,018)
(2,961)
Tax Rate
NOPAT
(10,376)
(105,173)
(86,659)
Net income
(569)
-99.42%
(97,299)
20.65%
(80,648)
145.24%
Dividends
Dividend yield
Proceeds from repurchase of equity
30,230
648
107,712
BB yield
-26.42%
-0.62%
-38.78%
Debt
Debt current
9,178
4,082
3,618
Long-term debt
23,359
27,950
36,112
Deferred revenue
80,048
180,059
125,660
Other long-term liabilities
3,893
(3,595)
(4,610)
Net debt
(141,972)
(162,535)
(266,413)
Cash flow
Cash from operating activities
(56,035)
(110,788)
(119,031)
CAPEX
(840)
(1,740)
(1,609)
Cash from investing activities
(150,674)
98,260
22,489
Cash from financing activities
30,230
648
110,213
FCF
(5,533)
(100,872)
(82,536)
Balance
Cash
174,509
193,650
305,226
Long term investments
917
917
Excess cash
169,448
191,909
302,664
Stockholders' equity
(723,352)
(722,868)
(533,965)
Invested Capital
773,559
831,638
766,068
ROIC
ROCE
EV
Common stock shares outstanding
73,808
65,740
64,147
Price
1.55
-3.13%
1.60
-63.05%
4.33
-33.89%
Market cap
114,403
8.76%
105,184
-62.13%
277,756
-8.10%
EV
(27,569)
(57,351)
11,343
EBITDA
(4,309)
(104,748)
(86,914)
EV/EBITDA
6.40
0.55
Interest
2,018
Interest/NOPBT